Supplementary Box 1 | Contacts, funding sources and acknowledgements for preclinical Alzheimer
disease trials
Anti-Amyloid Treatment in Asymptomatic Alzheimer’s (A4) trial
Correspondence to: Reisa A. Sperling reisa@rics.bwh.harvard.edu
Funded by National Institute on Aging (NIA) grant U19 AG10483 (Paul S. Aisen, Reisa A. Sperling), Eli
Lilly and Co., the Alzheimer’s Association, and several anonymous philanthropic organizations. The
A4 investigators wish to acknowledge the contributions of colleagues from the Alzheimer’s Disease
Cooperative Study, the Harvard Aging Brain Study (NIA grant P01 AG036694), Eli Lilly and Co.,
CogState, and the Mayo Clinic. A full list of acknowledgments can be found at
http://www.adcs.org/Studies/A4.aspx.
Alzheimer’s Prevention Initiative (API) trials
Correspondence to: Eric M. Reiman eric.reiman@bannerhealth.com
Funded by NIA grants RF1 AG041705 (Eric M. Reiman, Pierre N. Tariot), UF1 AG046150 (Eric M.
Reiman, Pierre N. Tariot), R01 AG031581 (Eric M. Reiman), P30 AG19610 (Eric M. Reiman),
Colciencias Universidad de Antioquia #111565741185 (Francisco Lopera), Genentech, Banner
Alzheimer’s Foundation, Anonymous Foundation, Nomis Foundation, Geoffrey Beene Gives Back
Alzheimer’s Initiative, Arizona Alzheimer’s Consortium, and the State of Arizona. API investigators
wish to acknowledge the contributions of colleagues from the Banner Alzheimer’s Institute,
University of Antioquia Grupo de Neurosciencias, Genentech, Novartis Pharma AG, their other
colleagues and collaborators, academic advisors, and their valued research participants.
Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) trials
Correspondence to: Randall J. Bateman batemanr@wustl.edu
DIAN is funded by NIA grant U19 AG032438 (John C. Morris) and the German Center for
Neurodegenerative Diseases (DZNE). The DIAN-TU recognizes the significant contributions of our
participants and family members. DIAN-TU receives funding support from the Alzheimer’s
Association, NIA U01 AG042791 (Randall J. Bateman), R01 AG046179 (Randall J. Bateman), Lilly,
Roche, DIAN Pharma Consortium (Biogen Idec, Eisai, Elan Pharmaceuticals, Eli Lilly and Company,
FORUM Pharmaceuticals, Hoffman La-Roche, Genentech, Janssen Alzheimer Immunotherapy,
Mithridion, Novartis Pharma AG, Pfizer Biotherapeutics Research & Development, Sanofi-Aventis),
Avid Radiopharmaceuticals and philanthropic foundations. DIAN-TU also receives trial support from
Avid, CogState, and Molecular NeuroImaging. The DIAN-TU investigators acknowledge the
contributions of colleagues from the Familial Adult Children Study (NIA grant P01 AG02627603S1),
Lifespan, University of Michigan, Mayo Clinic. Brown School of Medicine, Indiana University,
University of Rochester and the DIAN-TU Trial performance sites (full site list at http://www.diantu.org).
TOMMORROW study
Correspondence to: Allen D. Roses allen.roses@duke.edu
We wish to acknowledge the Takeda–Zinfandel Alliance clinical development team for the
TOMMORROW programme led by our collaborators Drs Steve Brannan, Daniel Burns and Kumar
Budur; the Neuropsychology Lead Office at Duke University including Kathleen Hayden, Heather
Romero and Brenda Plassman; the team at NeuroCog Trials directed by Richard Keefe; and the
members of the Neuropsychology Advisory Board to the TOMMORROW programme comprised of
Drs Mark Espeland, Mary Sano, Lon Schneider, Suzanne Craft and Andreas Monsch. We also thank Dr
Oksana Makeeva and her team in Tomsk, as well as Zara Meliykan in Moscow, for their expert input
on cultural adaptation and neuropsychological approaches in Russian investigations.